<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2507">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04655521</url>
  </required_header>
  <id_info>
    <org_study_id>109/20</org_study_id>
    <nct_id>NCT04655521</nct_id>
  </id_info>
  <brief_title>Dynamics of the Immune Response to COVID-19 / Infection by SARS-CoV-2</brief_title>
  <acronym>DIRECTOR</acronym>
  <official_title>The Dynamics of the Immune Response to Infection by SARS Coronavirus 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universit채t des Saarlandes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MeMed Diagnostics Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universit채t des Saarlandes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate host-immune biomarkers including TRAIL, IP-10, CRP and their computational&#xD;
      integration for predicting COVID-19 and disease severity in patients with PCR-confirmed&#xD;
      COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2, 2020</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Differential expression of biomarkers between COVID-19 and controls</measure>
    <time_frame>up to 90 days</time_frame>
    <description>Differential expression of TRAIL, IP-10, CRP, and their computational integration in subjects with COVID-19, as compared to control subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Differential expression of biomarkers between severe and non-severe COVID-19</measure>
    <time_frame>up to 90 days</time_frame>
    <description>Differential expression of TRAIL, IP-10, CRP, and their computational integration in subjects with COVID-19, who require more extensive medical intervention (i.e., exhibit severe symptoms), i.e. severe infection vs. non-severe infection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of biomarkers with disease severity</measure>
    <time_frame>up to 90 days</time_frame>
    <description>Correlation between host-immune biomarkers including TRAIL, IP-10, CRP, and their computational integration for predicting disease severity in patients with COVID-19, where measures of severity include ICU admission, respiratory failure, mechanical ventilation, septic shock, non-respiratory organ failure, and mortality.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarkers depending on therapy</measure>
    <time_frame>up to 90 days</time_frame>
    <description>Differential expression of TRAIL, IP-10, CRP, and their computational integration in subjects with COVID-19 with or without specific therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers depending on bacterial co-infection</measure>
    <time_frame>up to 90 days</time_frame>
    <description>Differential expression of TRAIL, IP-10, CRP, and their computational integration in subjects with COVID-19 with or without bacterial co-infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of biomarkers with viral load</measure>
    <time_frame>up to 90 days</time_frame>
    <description>Correlation between host-immune biomarkers including TRAIL, IP-10, CRP, and their computational integration with infectiousness, i.e. e.g. viral load.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>COVID-19</condition>
  <condition>SARS-CoV-2</condition>
  <condition>Viral Infection</condition>
  <arm_group>
    <arm_group_label>COVID-19 patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-COVID-19 patients with respiratory tract infection</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Eligible subjects 3 months and older with suspicion of COVID-19 that present to the&#xD;
        hospital due to suspected COVID-19. Controls with respiratory tract infection&#xD;
        (Non-COVID-19) and healthy controls&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
          -  confirmed infection with SARS-CoV-2 (except for the controls)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  n/a&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cihan Papan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universit채t des Saarlandes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cihan Papan, MD</last_name>
    <phone>004968411623943</phone>
    <email>cihan.papan@uks.eu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Saarland University</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cihan Papan, MD</last_name>
      <phone>004968411623943</phone>
      <email>cihan.papan@uks.eu</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Oved K, Cohen A, Boico O, Navon R, Friedman T, Etshtein L, Kriger O, Bamberger E, Fonar Y, Yacobov R, Wolchinsky R, Denkberg G, Dotan Y, Hochberg A, Reiter Y, Grupper M, Srugo I, Feigin P, Gorfine M, Chistyakov I, Dagan R, Klein A, Potasman I, Eden E. A novel host-proteome signature for distinguishing between acute bacterial and viral infections. PLoS One. 2015 Mar 18;10(3):e0120012. doi: 10.1371/journal.pone.0120012. eCollection 2015.</citation>
    <PMID>25785720</PMID>
  </reference>
  <reference>
    <citation>van Houten CB, de Groot JAH, Klein A, Srugo I, Chistyakov I, de Waal W, Meijssen CB, Avis W, Wolfs TFW, Shachor-Meyouhas Y, Stein M, Sanders EAM, Bont LJ. A host-protein based assay to differentiate between bacterial and viral infections in preschool children (OPPORTUNITY): a double-blind, multicentre, validation study. Lancet Infect Dis. 2017 Apr;17(4):431-440. doi: 10.1016/S1473-3099(16)30519-9. Epub 2016 Dec 22.</citation>
    <PMID>28012942</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 2, 2020</study_first_submitted>
  <study_first_submitted_qc>December 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2020</study_first_posted>
  <last_update_submitted>December 12, 2020</last_update_submitted>
  <last_update_submitted_qc>December 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universit채t des Saarlandes</investigator_affiliation>
    <investigator_full_name>Cihan Papan</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

